Anpheros Search · Treatment

Brivaracetam

Also known as: Briviact (in Italy: Nubriveo) · Brivaracetam Oral Solution · Briviact

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

Brivaracetam is indicated in the European Union as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. In the United States, it is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. The medicine is listed by the cited source as having an approved use for epilepsy.

From: Source: European Medicines Agency (EMA), Briviact (in Italy: Nubriveo) — EPAR, 27/01/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
1739745 brivaracetam
EMA
EMEA/H/C/003898

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

FDA (USA) Briviact

1 INDICATIONS AND USAGE BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. ( 1 )

Data provided by the U.S. Food and Drug Administration.

Document date: 20260820 · Official document →

EMA (EU) Briviact (in Italy: Nubriveo)

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

Source: European Medicines Agency (EMA), Briviact (in Italy: Nubriveo) — EPAR, 27/01/2026. © European Medicines Agency.

Document date: 27/01/2026 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Brivaracetam approved for in the European Union?

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. (Source: European Medicines Agency (EMA), Briviact (in Italy: Nubriveo) — EPAR, 27/01/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Data provided by the U.S. Food and Drug Administration.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Briviact (in Italy: Nubriveo) — EPAR, 27/01/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →